When combined with anti-CTLA-4, the PIC + RT in situ vaccination enabled greater tumor response and improved survival as well as tumor-specific immune memory and robust systemic anti-tumor immunity at tumors not directly treated by RT or PIC injection (Figs. 5 and  7). The gene discussed is CTLA4; the disease is neoplasm.